The Ideal Ventilator

BCV is the only therapeutic ventilation intervention that supports both inspiratory and expiratory work of breathing in a physiologically natural way, providing a real alternative to positive pressure techniques while avoiding most side effects. BCV allows patients to eat, speak and drink while their breathing is fully supported.

Better Patient Outcomes

BCV is an important therapeutic tool that can benefit multiple organ systems, particularly in this time when positive pressure appears to be a catalyst for worsening lung disease and many systemic side effects. 

BCV is a Cost Saving Tool

Biphasic Cuirass Ventilation has many available applications with the least amount of disposable items. It allows decreased use of sedation, decreases the overall risk of hospital-acquired infections, and reduces patients’ length of stay.  In the areas that drive the high costs associated with cardiopulmonary patients, BCV is a significant cost saver.

Work With Lungs, Not Against Them

The Ideal Ventilator

A Truly Physiological Way to Ventilate

Biphasic Cuirass Ventilation (BCV) is often the ideal ventilator by virtue of the way it mimics and supplements the natural pressure changes in the chest. It has been found to be able to support gas exchange and enhance the delicate failing cardiopulmonary interaction.

Increase Patient Independence

the Hayek RTX facilitates therapy while allowing the patient the potential to eat and vocalize. This allows the individual to continue to participate in their own care. The mobility that is allowed for while using this device will also assist in preventing skin breakdown and peripheral clotting both associated with the immobility that is necessary for more invasive forms of ventilation.

Clinical Benefits

BCV therapy provides a host of clinical benefits incuding:

  • Improved PaO2/FiO2 ratio.
  • Does not require significant sedation.
  • Increases and restores FRC.
  • Increased cardiac output.
  • Can be combined with other ventilation.
  • Facilitation of secretion flow from the lungs.
  • Improved pulmonary compliance as well as patient compliance with therapy
  • Reversal of atelectasis
  • Supports more expeditious weaning from PPV
  • Decreases intubation and reintubation rates
  • Heals persistent air leaks
  • Improves cardiac pre-load

 

 

Get Patients Healthier, Faster

Better Patient Outcomes

Ventilation with active exhalation means the Hayek RTX is particularly efficient for CO2 clearance. The non-mask cuirass interface allows avoidance of the side effects typically associated with facial mask or invasive positive pressure ventilation.

Alveolar Recruitment

Lung inflation with negative pressure is more homogenous and less injurious. Recruitment maneuvers with Continuous Negative Pressure are safer, more effective than PP LRMs, can help to decrease PEEP and need for proning.

Cardiac Output

By mimicking the natural intrathoracic pressure wave of spontaneous respiration, BCV facilitates cardiac function in a similar way.

Weaning

Support of FRC with BCV Continuous Negative mode can provide a game changing adjunct when normal weaning approaches are failing.
From the ER to Homecare

How does BCV make a difference across the spectrum of care?

Learn why these medical professionals strongly believe in BCV, and let them explain the value it can bring Hospitals, ICUs, LTACHs and Home Care patients.

BCV can help manage the symptoms associated with many conditions affecting the lungs, including but not limited to ALS, COPD, ARDS And Many More!

Better Outcomes, with a Reduced Cost

BCV is a Cost-Saving Tool

Decrease Hospitalization

When Biphasic Cuirass Ventilation is implemented at the earliest onset of respiratory symptoms, you can prevent infections and further hospitalization, ultimately reducing facility costs as conditions like COPD can place a major economic burden on healthcare systems. “In contrast, patients with COPD who were on the Pulmonary Rehabilitation (PR) program (PR with BCV) had spent significantly less medical cost per person-year in ER visits and hospitalization compared to those of the control group (PR only).”

Prevent Costly Side-effects

For cardiopulmonary patients, BCV significantly reduces high cost drivers associated with pharmacy, infection control, disposables, and length of stay.

In addition, patients who use BCV are not exposed to the risks of Ventilator Associated Events including Ventilator Associated Pneumonia, which can have costs upwards of $40 000(USD) per case.  

Prevent Re-admission

If a patient suffers a chronic condition, BCV™ is an option for home use to help prevent frequent hospitalization, with home users reporting significantly reduced admission rates to hsopitals, and greater time between trips to the hospital.

Want to Get Started?

Contact us to find out how our team of professionals can get you started with BCV